INS and gestational diabetes: This effect may result from olanzapine-induced antagonism of muscarinic receptors (M3) in the pancreatic islet cells, ultimately attenuating insulin release.[84,85] Atypical antipsychotics can also alter insulin response to glycemia changes by antagonizing the serotonergic (5HT(2)) and dopamine D(2)-like receptor-mediated release of insulin.[86] Due to these potential disrupting effects on insulin sensitivity and glucose regulation, atypical antipsychotics may favor the development of GDM.